The effects of DPP4 inhibitors, SGLT2 inhibitors and GLP1-RA on the AGE/RAGE pathway: implications for diabetes and its complications
Glycoconjugate Journal · 2025-12 · 42 (5-6) · 225-238
DOI: 10.1007/s10719-025-10197-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Glycoconjugate Journal, online erschienen am 14.10.2025. Verfasst von Sajad Abolfazli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, School of Pharmacy, Mazandaran University of Medical Science, Sari, Iran. Hauptthemen laut MEDLINE: Glycation End Products, Advanced, Dipeptidyl-Peptidase IV Inhibitors, Receptor for Advanced Glycation End Products, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 188 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
It is predicted that by 2045, diabetes will affect approximately 700 million individuals worldwide with increased morbidity, mortality and healthcare costs. Diabetes results in both microvascular and macrovascular complications, resulting in end-organ damage of blindness, renal failure, neuropathy and amputations, and increased cardiovascular disease, resulting in an enhanced mortality rate. The pathophysiology of diabetic complications involves the development of advanced glycation end products (AGEs) through nonenzymatic glycation interactions with proteins and nucleic acids, which is exacerbated by the persistent hyperglycemic state in type 2 diabetes mellitus. A key player in this process is the cellular receptor for AGEs, known as RAGE. AGEs activate RAGE by initiating various signalling pathways that contribute to increased oxidative stress and inflammation. These detrimental effects include impaired insulin signalling, disruption of metabolic homeostasis, toxicity to pancreatic beta cells, and epigenetic changes. To address diabetes glycemic control and its associated complications, several classes of drugs have been introduced to the market. Among them are GLP-1 agonists, DPP-4 inhibitors, and SGLT2 inhibitors. These medications employ different mechanisms of action to achieve glycemic control and have additional benefits. One such mechanism involves targeting the AGE/RAGE pathway, which reduces oxidative stress and inflammation by decreasing the formation of AGEs and suppressing RAGE expression in various organs. This approach shows potential in improving diabetes management and mitigating its resultant diabetes-related complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, School of Pharmacy, Mazandaran University of Medical Science, Sari, Iran.
- Research Department, Royal College of Surgeons in Ireland Bahrain, Adliya, Bahrain.
- Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. amir_saheb2000@yahoo.com.
- Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India. amir_saheb2000@yahoo.com.
- Applied Biomedical Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran. amir_saheb2000@yahoo.com.
Zitieren
APA
Abolfazli, S., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2025). The effects of DPP4 inhibitors, SGLT2 inhibitors and GLP1-RA on the AGE/RAGE pathway: implications for diabetes and its complications. Glycoconjugate Journal, 42(5-6), 225-238. https://doi.org/10.1007/s10719-025-10197-8
Vancouver
Abolfazli S, Atkin SL, Jamialahmadi T, Sahebkar A. The effects of DPP4 inhibitors, SGLT2 inhibitors and GLP1-RA on the AGE/RAGE pathway: implications for diabetes and its complications. Glycoconjugate Journal. 2025;42(5-6):225-238. doi:10.1007/s10719-025-10197-8
BibTeX
@article{Abolfazli2025,
author = {Abolfazli, Sajad and Atkin, Stephen L and Jamialahmadi, Tannaz and Sahebkar, Amirhossein},
title = {The effects of DPP4 inhibitors, SGLT2 inhibitors and GLP1-RA on the AGE/RAGE pathway: implications for diabetes and its complications},
journal = {Glycoconjugate Journal},
year = {2025},
volume = {42},
number = {5-6},
pages = {225--238},
doi = {10.1007/s10719-025-10197-8}
}
EUVIMED